Accordingly, inhibition of glutamine metabolism by GLS inhibitors selectively induces apoptosis in Myc-overexpressing tumor cells.75–80 Of note, CB-839, a potent and selective GLS inhibitor, is currently in phase I clinical studies for treating leukemias and other hematological tumors with Myc deregulation.81 Here, MYC is linked to hematopoietic and lymphoid cell neoplasm.